Human trials for Streptococcus A vaccine

February 28, 2013

Griffith University's Institute for Glycomics has launched human trials for a vaccine against Streptococcus A, the germ that causes rheumatic fever.

Severe damage to a patient's heart is just one of the possible long term consequences of . Former Prime Minister Kevin Rudd has twice had heart surgery to repair damage suffered from rheumatic fever when he was a child.

Professor Michael Good, Principal Research Leader at the Institute for Glycomics has devoted more than 20 years to beating this disease. The key to the vaccine lies in targeting a particular protein found on the surface of Strep A bacteria.

"Previous studies have shown that the vaccine induces a very effective immune response in rabbits and mice," Professor Good said.

"The next important step is to ensure that it is safe and does not cause any adverse effects in people, in particular that the vaccine itself doesn't cause any ."

Professor James McCarthy, Head of the Infectious Diseases program at the Queensland Institute of Medical Research will carry out the year-long trial involving 20 healthy adults.

"Participants will be monitored very closely for the next 12 months," Professor McCarthy said.

"Each volunteer will be given two doses of the and we'll be watching carefully for any signs of heart problems."

Rheumatic fever is a major issue in remote Aboriginal and Torres Strait Islander communities in .

"Infection rates in these remote Queensland communities are among the highest in the world. Nine out of every ten sufferers in this State are Aboriginal or Torres Strait Islander people," Professor Good said.

Explore further: Effects of chewing wild tobacco during pregnancy: study

Related Stories

New approaches to combating rheumatic fever in children

February 5, 2013

Leading international researchers and doctors are meeting at the University of Otago, Wellington this week to identify new approaches to reducing the very high levels of rheumatic fever in New Zealand and Australia.

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.